Robert S. Epstein
CIK: 0001252004
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (12 total)
- Jun 12, 2026FATE
FATE THERAPEUTICS INC
Award(A)DirectStock Option (Right to Buy)
87.9K shares- - Jun 11, 2026VCYT
VERACYTE, INC.
Award(A)Direct5.3K shares- - May 20, 2026VCYT
VERACYTE, INC.
Sale(S)Direct10K shares at avg. $44.01$440K - May 5, 2026FATE
FATE THERAPEUTICS INC
Exercise(M)Direct25K shares at avg. $1.69$42K - Oct 1, 2025VCYT
VERACYTE, INC.
Sale(S)Direct21.5K shares at avg. $35.08$753K - Oct 1, 2025VCYT
VERACYTE, INC.
Exercise(M)Direct10K shares at avg. $7.94$79K - Jun 18, 2025VCYT
VERACYTE, INC.
Award(A)Direct9.3K shares- - May 29, 2025FATE
FATE THERAPEUTICS INC
Award(A)DirectStock Option (Right to Buy)
55K shares- - May 21, 2025ILMN
ILLUMINA, INC.
Award(A)Direct3.8K shares- - Jan 6, 2025VCYT
VERACYTE, INC.
Exercise(M)Direct20K shares at avg. $8.04$161K - Nov 12, 2024VCYT
VERACYTE, INC.
Sale(S)Direct15K shares at avg. $38.32$575K - Nov 12, 2024VCYT
VERACYTE, INC.
Exercise(M)Direct15K shares at avg. $8.04$121K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 12, 2026 |  FATE FATE THERAPEUTICS INC | Award(A) Stock Option (Right to Buy) | 87,900 | - | - | Direct |
| Jun 11, 2026 |  VCYT VERACYTE, INC. | Award(A) | 5,272 | - | $0 | Direct |
| May 20, 2026 | VCYT VERACYTE, INC. | Sale(S) | 10,000 | $44.01 | $440,129 | Direct |
| May 5, 2026 | FATE FATE THERAPEUTICS INC | Exercise(M) | 25,000 | $1.69 | $42,250 | Direct |
| Oct 1, 2025 | VCYT VERACYTE, INC. | Sale(S) | 21,473 | $35.08 | $753,204 | Direct |
| Oct 1, 2025 | VCYT VERACYTE, INC. | Exercise(M) | 10,000 | $7.94 | $79,400 | Direct |
| Jun 18, 2025 | VCYT VERACYTE, INC. | Award(A) | 9,321 | - | - | Direct |
| May 29, 2025 | FATE FATE THERAPEUTICS INC | Award(A) Stock Option (Right to Buy) | 55,000 | - | - | Direct |
| May 21, 2025 |  ILMN ILLUMINA, INC. | Award(A) | 3,780 | - | - | Direct |
| Jan 6, 2025 | VCYT VERACYTE, INC. | Exercise(M) | 20,000 | $8.04 | $160,800 | Direct |
| Nov 12, 2024 | VCYT VERACYTE, INC. | Sale(S) | 15,000 | $38.32 | $574,830 | Direct |
| Nov 12, 2024 | VCYT VERACYTE, INC. | Exercise(M) | 15,000 | $8.04 | $120,600 | Direct |
1-12 of 12 transactions
About EPSTEIN ROBERT S
EPSTEIN ROBERT S (SEC CIK 0001252004) files insider reports with the SEC as Director of VERACYTE, INC. (VCYT), Director of FATE THERAPEUTICS INC (FATE) and Director of ILLUMINA, INC. (ILMN).
Signal8 holds 10 ownership filings by EPSTEIN ROBERT S, all Form 4s, filed between Nov 14, 2024 and Jun 15, 2026. Those filings report 12 transactions, from Nov 12, 2024 to Jun 12, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on EPSTEIN ROBERT S's filings is in SAN DIEGO, CA.
Recent filings by EPSTEIN ROBERT S
- Jun 12, 2026: Grant or award of FATE derivative securities (Form 4, code A).
- Jun 11, 2026: Grant or award of VCYT shares (Form 4, code A).
- May 20, 2026: Open-market sale of VCYT shares (Form 4, code S).
- May 5, 2026: Option exercise of FATE shares (Form 4, code M).
- Oct 1, 2025: Open-market sale of VCYT shares (Form 4, code S).
Other insiders filing for VERACYTE, INC. (VCYT)
- Wygant Jonathan, VP, Chief Accounting Officer
- Holstein Jens, Director
- EASTHAM KARIN, Director
- Bhanji Muna, Director
- Leite John, Global Chief Commercial Off
- Febbo Phillip G., Chief Scientific & Med Officer